- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/24 - Antidepressants
Patent holdings for IPC class A61P 25/24
Total number of patents in this class: 4586
10-year publication summary
|
123
|
199
|
247
|
261
|
310
|
340
|
391
|
370
|
341
|
51
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Antecip Bioventures II LLC | 349 |
81 |
| Takeda Pharmaceutical Company Limited | 2713 |
69 |
| Janssen Pharmaceutica N.V. | 3307 |
66 |
| GH Research Ireland Limited | 80 |
62 |
| F. Hoffmann-La Roche AG | 7875 |
58 |
| Sage Therapeutics, Inc. | 379 |
58 |
| Taisho Pharmaceutical Co., Ltd. | 863 |
42 |
| Hoffmann-La Roche Inc. | 3612 |
40 |
| Janssen Pharmaceuticals, Inc. | 437 |
37 |
| H. Lundbeck A/S | 1252 |
35 |
| Intra-Cellular Therapies, Inc. | 428 |
33 |
| Sumitomo Dainippon Pharma Co., Ltd. | 211 |
27 |
| Gilgamesh Pharmaceuticals, Inc. | 63 |
27 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 855 |
26 |
| Boehringer Ingelheim International GmbH | 4579 |
25 |
| The Trustees of Columbia University in the City of New York | 3614 |
25 |
| The Regents of the University of California | 20378 |
24 |
| AstraZeneca AB | 2826 |
24 |
| Sunshine Lake Pharma Co., Ltd. | 613 |
24 |
| LTS Lohmann Therapie-Systeme AG | 693 |
23 |
| Other owners | 3780 |